Log in | Register

Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric)

Cédric Bretonnière| Marc Leone| Christophe Milési| Bernard Allaouchiche| Laurence Armand-Lefevre| Olivier Baldesi| Lila Bouadma| Dominique Decré| Samy Figueiredo| Rémy Gauzit| Benoît Guery| Nicolas Joram| Boris Jung| Sigismond Lasocki| Alain Lepape| Fabrice Lesage| Olivier Pajot| François Philippart| Bertrand Souweine| Pierre Tattevin| Jean-François Timsit| Renaud Vialet| Jean Ralph Zahar| Benoît
Conference Reports and Expert Panel
Volume 41, Issue 7 / July , 2015

Pages 1181 - 1196

Abstract

Emerging resistance to antibiotics shows no signs of decline. At the same time, few new antibacterials are being discovered. There is a worldwide recognition regarding the danger of this situation. The urgency of the situation and the conviction that practices should change led the Société de Réanimation de Langue Française (SRLF) and the Société Française d’Anesthésie et de Réanimation (SFAR) to set up a panel of experts from various disciplines. These experts met for the first time at the end of 2012 and have since met regularly to issue the following 67 recommendations, according to the rigorous GRADE methodology. Five fields were explored: i) the link between the resistance of bacteria and the use of antibiotics in intensive care; ii) which microbiological data and how to use them to reduce antibiotic consumption; iii) how should antibiotic therapy be chosen to limit consumption of antibiotics; iv) how can antibiotic administration be optimized; v) review and duration of antibiotic treatments. In each institution, the appropriation of these recommendations should arouse multidisciplinary discussions resulting in better knowledge of local epidemiology, rate of antibiotic use, and finally protocols for improving the stewardship of antibiotics. These efforts should contribute to limit the emergence of resistant bacteria.

Keywords

References

  1. So A, Furlong M, Heddini A (2010) Globalisation and antibiotic resistance. BMJ 341:c5116
    • View reference on PubMed
    • View reference on publisher's website
  2. Bassetti M, Merelli M, Temperoni C, Astilean A (2013) New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 12:22
    • View reference on PubMed
    • View reference on publisher's website
  3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12
    • View reference on PubMed
    • View reference on publisher's website
  4. Corona A, Colombo R (2013) Towards the end of the antibiotic era: let’s save the ancient soldier Colistin! Intensive Care Med 39:1660–1661
  5. WHO (2014) Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva, p 256
  6. Carlet J (2012) World Alliance Against Antibiotic Resistance (WAAR): safeguarding antibiotics. Intensive Care Med 38:1723–1724
  7. Paiva JA (2013) Adding risk factors for potentially resistant pathogens, increasing antibiotic pressure and risk creating the untreatable bacteria: time to change direction. Intensive Care Med 39:779–781
  8. Damas P, Canivet JL, Ledoux D, Monchi M, Melin P, Nys M, De Mol P (2006) Selection of resistance during sequential use of preferential antibiotic classes. Intensive Care Med 32:67–74
  9. Timsit JF, Harbarth S, Carlet J (2014) De-escalation as a potential way of reducing antibiotic use and antimicrobial resistance in ICU. Intensive Care Med 40:1580–1582
  10. Visscher S, Schurink CA, Melsen WG, Lucas PJ, Bonten MJ (2008) Effects of systemic antibiotic therapy on bacterial persistence in the respiratory tract of mechanically ventilated patients. Intensive Care Med 34:692–699
  11. Brusselaers N, Vogelaers D, Blot S (2011) The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 1:47
    • View reference on PubMed
    • View reference on publisher's website
  12. Michalopoulos AS, Falagas ME (2011) Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 1:30
    • View reference on PubMed
    • View reference on publisher's website
  13. Hanberger H, Arman D, Gill H, Jindrak V, Kalenic S, Kurcz A, Licker M, Naaber P, Scicluna EA, Vanis V, Walther SM (2009) Surveillance of microbial resistance in European intensive care units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med 35:91–100
  14. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, Nicolau DP, Paiva JA, Tumbarello M, Welte T, Wilcox M, Zahar JR, Poulakou G (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776–795
  15. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490
    • View reference on PubMed
    • View reference on publisher's website
  16. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ Clin Res 336:924–926
    • View reference on publisher's website
  17. GRADE Working Group (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490
    • View reference on publisher's website
  18. Fitch K, Bernstein S, Aguilar M, Burnand B et al (2001) The RAND/UCLA appropriateness method user’s manual. RAND, Santa Monica
  19. DiazGranados CA (2012) Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes. Am J Infect Control 40:526–529
    • View reference on PubMed
    • View reference on publisher's website
  20. Kim JW, Chung J, Choi SH, Jang HJ, Hong SB, Lim CM, Koh Y (2012) Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. Critical Care 16:R28
    • View reference on PubMed
    • View reference on publisher's website
  21. Nijssen S, Fluit A, van de Vijver D, Top J, Willems R, Bonten MJ (2010) Effects of reducing beta-lactam antibiotic pressure on intestinal colonization of antibiotic-resistant gram-negative bacteria. Intensive Care Med 36:512–519
  22. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N (2011) Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 66:1223–1230
    • View reference on PubMed
    • View reference on publisher's website
  23. Kuster SP, Ruef C, Ledergerber B, Hintermann A, Deplazes C, Neuber L, Weber R (2008) Quantitative antibiotic use in hospitals: comparison of measurements, literature review, and recommendations for a standard of reporting. Infection 36:549–559
    • View reference on PubMed
    • View reference on publisher's website
  24. Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Manolas K (2007) De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 33:1533–1540
  25. Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernandez-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Marquez-Vacaro JA (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40:32–40
  26. Mokart D, Slehofer G, Lambert J, Sannini A, Chow-Chine L, Brun JP, Berger P, Duran S, Faucher M, Blache JL, Saillard C, Vey N, Leone M (2014) De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med 40:41–49
  27. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, Tenaillon A (2000) Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 132:621–630
    • View reference on PubMed
    • View reference on publisher's website
  28. Swanson JM, Wood GC, Croce MA, Mueller EW, Boucher BA, Fabian TC (2008) Utility of preliminary bronchoalveolar lavage results in suspected ventilator-associated pneumonia. J Trauma 65:1271–1277
    • View reference on PubMed
    • View reference on publisher's website
  29. Canadian Critical Care Trials Group (2006) A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 355:2619–2630
    • View reference on publisher's website
  30. O’Horo JC, Thompson D, Safdar N (2012) Is the gram stain useful in the microbiologic diagnosis of VAP? A meta-analysis. Clin Infect Dis 55:551–561
    • View reference on PubMed
    • View reference on publisher's website
  31. Galar A, Yuste JR, Espinosa M, Guillen-Grima F, Hernaez-Crespo S, Leiva J (2012) Clinical and economic impact of rapid reporting of bacterial identification and antimicrobial susceptibility results of the most frequently processed specimen types. Eur J Clin Microbiol Infect Dis 31:2445–2452
    • View reference on PubMed
    • View reference on publisher's website
  32. Kerremans JJ, Verboom P, Stijnen T, Hakkaart-van Roijen L, Goessens W, Verbrugh HA, Vos MC (2008) Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother 61:428–435
    • View reference on PubMed
    • View reference on publisher's website
  33. Vlek AL, Bonten MJ, Boel CH (2012) Direct matrix-assisted laser desorption ionization time-of-flight mass spectrometry improves appropriateness of antibiotic treatment of bacteremia. PLoS One 7:e32589
    • View reference on PubMed
    • View reference on publisher's website
  34. Perez KK, Olsen RJ, Musick WL, Cernoch PL, Davis JR, Land GA, Peterson LE, Musser JM (2013) Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med 137:1247–1254
    • View reference on PubMed
    • View reference on publisher's website
  35. Lasocki S, Scanvic A, Le Turdu F, Restoux A, Mentec H, Bleichner G, Sollet JP (2006) Evaluation of the Binax NOW Streptococcus pneumoniae urinary antigen assay in intensive care patients hospitalized for pneumonia. Intensive Care Med 32:1766–1772
  36. Falguera M, Ruiz-Gonzalez A, Schoenenberger JA, Touzon C, Gazquez I, Galindo C, Porcel JM (2010) Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia. Thorax 65:101–106
    • View reference on PubMed
    • View reference on publisher's website
  37. Matta M, Kerneis S, Day N, Lescat M, Hoi AB, Varon E, Gutmann L, Mainardi JL (2010) Do clinicians consider the results of the BinaxNOW Streptococcus pneumoniae urinary antigen test when adapting antibiotic regimens for pneumonia patients? Clin Microbiol Infect 16:1389–1393
    • View reference on PubMed
    • View reference on publisher's website
  38. Depuydt P, Benoit D, Vogelaers D, Decruyenaere J, Vandijck D, Claeys G, Verschraegen G, Blot S (2008) Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia. Intensive Care Med 34:675–682
  39. Jung B, Sebbane M, Chanques G, Courouble P, Verzilli D, Perrigault PF, Jean-Pierre H, Eledjam JJ, Jaber S (2009) Previous endotracheal aspirate allows guiding the initial treatment of ventilator-associated pneumonia. Intensive Care Med 35:101–107
  40. Joseph NM, Sistla S, Dutta TK, Badhe AS, Parija SC (2010) Ventilator-associated pneumonia: role of colonizers and value of routine endotracheal aspirate cultures. Int J Infect Dis 14:e723–e729
    • View reference on PubMed
    • View reference on publisher's website
  41. Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plesiat P, Andremont A (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57:1488–1495
    • View reference on PubMed
    • View reference on publisher's website
  42. Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Papas V, Pitsiolis T, Tsakris A, Nanas S, Roussos C (2013) Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients. Intensive Care Med 39:1253–1261
  43. Razazi K, Derde LP, Verachten M, Legrand P, Lesprit P, Brun-Buisson C (2012) Clinical impact and risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria in the intensive care unit. Intensive Care Med 38:1769–1778
  44. Andes D, Craig WA (2005) Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 11(Suppl 6):10–17
    • View reference on PubMed
    • View reference on publisher's website
  45. Nguyen HM, Shier KL, Graber CJ (2014) Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 69:871–880
    • View reference on PubMed
    • View reference on publisher's website
  46. Aubert G, Carricajo A, Vautrin AC, Guyomarc’h S, Fonsale N, Page D, Brunel P, Rusch P, Zeni F (2005) Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect 59:83–89
    • View reference on PubMed
    • View reference on publisher's website
  47. Nseir S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M, Onimus T, Saulnier F, Mathieu D, Durocher A (2005) First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 33:283–289
    • View reference on PubMed
    • View reference on publisher's website
  48. Charbonneau P, Parienti JJ, Thibon P, Ramakers M, Daubin C, du Cheyron D, Lebouvier G, Le Coutour X, Leclercq R (2006) Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 42:778–784
    • View reference on PubMed
    • View reference on publisher's website
  49. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ (2008) Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 47:1162–1170
    • View reference on PubMed
    • View reference on publisher's website
  50. Drieux L, Brossier F, Duquesnoy O, Aubry A, Robert J, Sougakoff W, Lecso-Bornet M, Jarlier V (2009) Increase in hospital-acquired bloodstream infections caused by extended spectrum beta-lactamase-producing Escherichiacoli in a large French teaching hospital. Euro J Clin Microbiol Infect Dis 28:491–498
    • View reference on publisher's website
  51. Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, Mensa J (2009) Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 63:568–574
    • View reference on PubMed
    • View reference on publisher's website
  52. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD (2010) Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 340:c2096
    • View reference on PubMed
    • View reference on publisher's website
  53. Berman SJ, Johnson EW, Nakatsu C, Alkan M, Chen R, LeDuc J (2004) Burden of infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis 39:1747–1753
    • View reference on PubMed
    • View reference on publisher's website
  54. El Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E (2004) Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis 39:474–480
    • View reference on PubMed
    • View reference on publisher's website
  55. Polverino E, Dambrava P, Cilloniz C, Balasso V, Marcos MA, Esquinas C, Mensa J, Ewig S, Torres A (2010) Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax 65:354–359
    • View reference on PubMed
    • View reference on publisher's website
  56. Scanvic A, Denic L, Gaillon S, Giry P, Andremont A, Lucet JC (2001) Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis 32:1393–1398
    • View reference on PubMed
    • View reference on publisher's website
  57. Lambotte O, Timsit JF, Garrouste-Orgeas M, Misset B, Benali A, Carlet J (2002) The significance of distal bronchial samples with commensals in ventilator-associated pneumonia: colonizer or pathogen? Chest 122:1389–1399
    • View reference on PubMed
    • View reference on publisher's website
  58. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665
    • View reference on PubMed
    • View reference on publisher's website
  59. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ (2013) Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration > 1 mg/L: a matched cohort study. Clin Infect Dis 56:1562–1569
    • View reference on PubMed
    • View reference on publisher's website
  60. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54:621–629
    • View reference on PubMed
    • View reference on publisher's website
  61. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP (2011) Vancomycin: we can not get there from here. Clin Infect Dis 52:969–974
    • View reference on PubMed
    • View reference on publisher's website
  62. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
  63. Yu KT, Wyer PC (2008) Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-h rule for initiation of antibiotic therapy in community-acquired pneumonia. Ann Emerg Med 51:651–662
    • View reference on PubMed
    • View reference on publisher's website
  64. Silber SH, Garrett C, Singh R, Sweeney A, Rosenberg C, Parachiv D, Okafo T (2003) Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest 124:1798–1804
    • View reference on PubMed
    • View reference on publisher's website
  65. SPILF (2009) 17th Consensus conference. Consensus conference on bacterial meningitis. Short text. Med Mal Infect 39:175–186
    • View reference on publisher's website
  66. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA (2012) Does beta-lactam pharmacokinetic variability in critically Ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2:35
    • View reference on PubMed
    • View reference on publisher's website
  67. Pletz MW, Lipman J (2013) Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing. Intensive Care Med 39:1322–1324
  68. Povoa P, Spriet I, Zahar JR (2014) Antibiotic dosing in the critically ill: asking the same questions but expecting different answers. Intensive Care Med 40:1780–1782
  69. Udy AA, Roberts JA, Lipman J (2013) Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 39:2070–2082
  70. Chatellier D, Jourdain M, Mangalaboyi J, Ader F, Chopin C, Derambure P, Fourrier F (2002) Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 28:214–217
  71. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10; quiz 11–12
    • View reference on PubMed
    • View reference on publisher's website
  72. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083
    • View reference on PubMed
    • View reference on publisher's website
  73. Mohr JF, Wanger A, Rex JH (2004) Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 48:125–130
    • View reference on PubMed
    • View reference on publisher's website
  74. Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725–1730
    • View reference on PubMed
    • View reference on publisher's website
  75. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ (2013) Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56:272–282
    • View reference on PubMed
    • View reference on publisher's website
  76. Spapen HD, Janssen van Doorn K, Diltoer M, Verbrugghe W, Jacobs R, Dobbeleir N, Honore PM, Jorens PG (2011) Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann Intensive Care 1:26
    • View reference on PubMed
    • View reference on publisher's website
  77. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J (2011) Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 55:2704–2709
    • View reference on PubMed
    • View reference on publisher's website
  78. Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA (2012) Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care 2:37
    • View reference on PubMed
    • View reference on publisher's website
  79. Legrand M, Max A, Schlemmer B, Azoulay E, Gachot B (2011) The strategy of antibiotic use in critically ill neutropenic patients. Ann Intensive Care 1:22
    • View reference on PubMed
    • View reference on publisher's website
  80. Gyssens IC, Kern WV, Livermore DM (2013) The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica 98:1821–1825
    • View reference on PubMed
    • View reference on publisher's website
  81. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S (2003) Comparison of 8 versus 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588–2598
    • View reference on PubMed
    • View reference on publisher's website
  82. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL (2000) Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162:505–511
    • View reference on PubMed
    • View reference on publisher's website
  83. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M (2010) Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–474
    • View reference on PubMed
    • View reference on publisher's website
  84. Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G (2012) An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 38:940–949
  85. Havey TC, Fowler RA, Daneman N (2011) Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 15:R267
    • View reference on PubMed
    • View reference on publisher's website
  86. Chong YP, Moon SM, Bang KM, Park HJ, Park SY, Kim MN, Park KH, Kim SH, Lee SO, Choi SH, Jeong JY, Woo JH, Kim YS (2013) Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother 57:1150–1156
    • View reference on PubMed
    • View reference on publisher's website
  87. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Torok ME, Walker S, Wertheim HF, Wilson P, Llewelyn MJ (2011) Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis 11:208–222
    • View reference on PubMed
    • View reference on publisher's website
  88. Rimawi RH, Mazer MA, Siraj DS, Gooch M, Cook PP (2013) Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. Crit Care Med 41:2099–2107
    • View reference on PubMed
    • View reference on publisher's website
  89. De Waele JJ, Bassetti M, Martin-Loeches I (2014) Impact of de-escalation on ICU patients’ prognosis. Intensive Care Med 40:1583–1585
  90. Kapoor G, Saigal S (2014) De-escalation in severe sepsis: still an important part of our armamentarium against antimicrobial resistance. Intensive Care Med 40:1618
  91. Leone M, Bechis C, Baumstarck K (2014) De-escalation in severe sepsis: still an important part of our armamentarium against antimicrobial resistance, of course! Intensive Care Med 40:1619
  92. Silva BN, Andriolo RB, Atallah AN, Salomao R (2013) De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev 3:CD007934
    • View reference on PubMed
  93. Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanese J, Jaber S, Lepape A, Constantin JM, Papazian L, Bruder N, Allaouchiche B, Bezulier K, Antonini F, Textoris J, Martin C (2014) De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 40:1399–1408
  94. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G (2010) Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect dis 51:1238–1244
    • View reference on PubMed
    • View reference on publisher's website
  95. Nair GB, Niederman MS (2015) Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med 41:34–48
  96. Palmer LB, Smaldone GC (2014) Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med 189:1225–1233
    • View reference on PubMed
    • View reference on publisher's website
  97. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH, Su DCSG (2013) Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 13:328–341
    • View reference on PubMed
    • View reference on publisher's website
  98. Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R (2012) A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 16:R218
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement